Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza ...

Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...

Novavax (NVAX) reached $7.64 at the closing of the latest trading day, reflecting a -2.55% change compared to its last close.

Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration ...

Investing.com -- Novavax (NASDAQ: NVAX) stock rose 5% after the company announced positive preclinical results for its H5N1 avian influenza vaccine candidate, showing strong immune responses in ...

Novavax's H5N1 avian pandemic influenza vaccine candidate demonstrates immunogenicity in preclinical study: Gaithersburg, Maryland Friday, July 25, 2025, 15:00 Hrs [IST] Novavax, ...

Novavax Inc. closed 61.37% short of its 52-week high of $17.81, which the company reached on July 26th.

Novavax, Inc. (NVAX) on Thursday announced preclinical data demonstrating that the company’s H5N1 bird flu vaccine candidate ...

Novavax Inc. closed 59.74% below its 52-week high of $17.81, which the company achieved on July 26th.

Novavax Inc. (NASDAQ:NVAX) is one of the best cheap stocks with huge upside potential. On June 11, BTIG maintained a Buy rating on Novavax Inc. (NASDAQ:NVAX) with a $19 price target. BTIG analyst ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...